(2-甲基-6-喹啉基)甲醇 | 108166-02-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: (2-甲基-6-喹啉基)甲醇
• 中文别名: (2-甲基-6-喹啉)甲醇；6-(羟甲基)-2-甲基喹啉；2-甲基喹啉-6-甲醇
• 英文名称: (2-methylquinolin-6-yl)methanol
• 英文别名: (2-methyl-6-quinolinyl)methanol
• CAS: 108166-02-5
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: HLFYJILNIBADGG-UHFFFAOYSA-N

物化性质

• 熔点：
  136-139
• 沸点：
  334.9±27.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933499090
• 安全说明：
  S22,S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  应存放在室温、密封和干燥的环境中。

SDS

Name:	(2-Methyl-6-quinolinyl)methanol Material Safety Data Sheet
Synonym:
CAS:	108166-02-5

Section 1 - Chemical Product MSDS Name:(2-Methyl-6-quinolinyl)methanol Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
108166-02-5	(2-Methyl-6-quinolinyl)methanol	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Keep under a nitrogen blanket.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 108166-02-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Off white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 136 - 139 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NO
Molecular Weight: 173.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, halogens, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 108166-02-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(2-Methyl-6-quinolinyl)methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 108166-02-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 108166-02-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 108166-02-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-甲基-6-喹啉基)甲醇 在 氯化亚砜 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 6,7-dimethoxy-4-((2-methylquinolin-6-yl)methyl)-1-propylisoquinolin-3-ol
  参考文献：
  名称：

  SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)

  摘要：

  本发明涉及具有以下公式的化合物 其中R'，R1，到R7和Ar如本文所述定义。这些化合物作为磷酸二酯酶10（PDE10A）的抑制剂，可用于治疗中枢神经系统疾病，如精神疾病，也可用于治疗例如肥胖、2型糖尿病、代谢综合征、葡萄糖不耐受、疼痛和眼科疾病。

  公开号：

  US20120214837A1
• 作为产物：
  描述：

  2-甲基喹啉-6-甲醛 在 sodium tetrahydroborate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.25h， 以100%的产率得到(2-甲基-6-喹啉基)甲醇
  参考文献：
  名称：

  SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)

  摘要：

  本发明涉及具有以下公式的化合物 其中R'，R1，到R7和Ar如本文所述定义。这些化合物作为磷酸二酯酶10（PDE10A）的抑制剂，可用于治疗中枢神经系统疾病，如精神疾病，也可用于治疗例如肥胖、2型糖尿病、代谢综合征、葡萄糖不耐受、疼痛和眼科疾病。

  公开号：

  US20120214837A1
• 作为试剂：
  描述：

  2-甲基喹啉-6-甲醛 、 硼氢化钠 在 ice 、 盐酸 、 四氢呋喃 、 二氯甲烷 、 Brine 、 Sodium sulfate-III 、 (2-甲基-6-喹啉基)甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 16.25h， 以to give (2-methylquinolin-6-yl)methanol SLA 47080A as a yellow oil (1.056 g, quant.)的产率得到(2-甲基-6-喹啉基)甲醇
  参考文献：
  名称：

  Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)

  摘要：

  本发明涉及以下式的化合物，其中R′，R1至R7和Ar的定义如本文所述。这些化合物可用作磷酸二酯酶10（PDE10A）的抑制剂，其在治疗中枢神经系统疾病，如精神病，以及在治疗肥胖症、2型糖尿病、代谢综合征、葡萄糖不耐受、疼痛和眼科疾病方面有用。

  公开号：

  US08772316B2

文献信息

• N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES
  申请人：BRANDL Trixi

  公开号：US20120035168A1

  公开（公告）日：2012-02-09

  The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及具有公式I的化合物，其中取代基如说明书中所定义；以自由形式或盐形式存在；及其制备方法，作为药品的使用，以及包含它的药品。
• Controlled Ligand Exchange Between Ruthenium Organometallic Cofactor Precursors and a Naïve Protein Scaffold Generates Artificial Metalloenzymes Catalysing Transfer Hydrogenation
  作者：George S. Biggs、Oskar James Klein、Sarah L. Maslen、J. Mark Skehel、Trevor J. Rutherford、Stefan M. V. Freund、Florian Hollfelder、Sally R. Boss、Paul D. Barker

  DOI：10.1002/anie.202015834

  日期：2021.5.3

  ligand exchange to unmask catalytic activity. By systematically testing RuII(η6‐arene)(bipyridine) complexes designed to facilitate the displacement of functionalised bipyridines, we develop a fast and robust procedure for generating new enzymes via ligand exchange in a protein that has not evolved to bind such a complex. The resulting metal cofactors form peptidic coordination bonds but also retain

  许多天然金属酶由蛋白质和生物合成复合物组装而成，通过改变金属配位产生有效的催化剂。在这里，我们采用相同的策略，利用配体交换来生成人工金属酶（ArM），以揭示催化活性。通过系统地测试旨在促进功能化联吡啶置换的 Ru II (η 6芳烃)(联吡啶)复合物，我们开发了一种快速而稳健的程序，通过在尚未进化到结合此类复合物的蛋白质中通过配体交换来生成新酶。所得金属辅助因子形成肽配位键，但也保留非生物配体。使用串联质谱和19 F NMR 光谱来表征有机金属辅因子并鉴定蛋白质衍生的配体。通过将钌辅助因子引入 4 螺旋束，生成了转移氢化催化剂，与溶液中的相应小分子反应相比，其速率提高了 35 倍。
• AROYLQUINOLINE COMPOUNDS
  申请人：Liou Jing-Ping

  公开号：US20110275643A1

  公开（公告）日：2011-11-10

  A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

  提供了一系列含有结构式（I）的硝基杂环衍生物。在结构式（I）中，P、Q和R1至R8在说明书中有定义。本发明揭示的衍生物具有抑制微管聚合的特性，并可使用合适的药用载体治疗癌症和其他与微管聚合有关的疾病。
• [EN] BENZYLAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZYLAMINE
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2014108679A1

  公开（公告）日：2014-07-17

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了化合物的公式(I)：包含这种化合物的组合物；在治疗中使用这种化合物（例如在涉及血浆激肽酶活性的疾病或病况的治疗或预防中）；以及使用这种化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z如本文所定义。
• SUBSTITUTED PYRAZOLE DERIVATIVES
  申请人：ITO Mitsuhiro

  公开号：US20090270359A1

  公开（公告）日：2009-10-29

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供一种新型吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供一种由下式表示的化合物(I′)：其中R1是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R2是苯基，带有氰基（苯基可能还有除氰基之外的取代基）；R3是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R4是可选地带有取代基的环状基团；X是亚甲基，可选地带有取代基，或CO，或其盐。